Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients

艰难梭菌患者中和抗毒素和表位的特征

基本信息

  • 批准号:
    10549285
  • 负责人:
  • 金额:
    $ 38.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-16 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Abstract Intestinal injury and inflammation in Clostridium difficile infection (CDI), an increasing cause of morbidity, mortality and financial cost in the US, is mediated by two large clostridial toxins: TcdA & TcdB. Although antibodies against each toxin have been shown to be associated with protection, it is unclear what types of antibodies and their epitopes are responsible for effective immunity against CDI in patients. The goal of this project is to define the characteristics of a protective humoral immune response in CDI and the major neutralizing TcdA & TcdB epitopes. The hypothesis is that host antibodies directed against major neutralizing epitopes in TcdA & TcdB confer protection against CDI. To test this hypothesis, we will first validate our preliminary finding on neutralizing anti-TcdA/TcdB responses that correlate protection against severe CDI will also correlate protection against recurrence (Aim 1); subsequently we will characterize C. difficile toxin-specific B cell responses at clonal level and correlate these with CDI disease progression and recurrence (Aim 2); and finally we will clone neutralizing antibodies from individual B cells to obtain a representative panel of human protective monoclonal antibodies against the two toxins and characterize their binding epitopes and reactivity to a variety of toxins produced by major C. difficile endemic and outbreak strains (Aim 3). The completion of these specific aims can lead to the discovery of antibody biomarkers that predict outcomes of the most significant clinical issues in CDI management, including CDI occurrence, severity, and recurrence. Identification and characterization of protective antibodies may also facilitate the development of novel passive immunotherapy and vaccine approaches.
摘要 艰难梭菌感染(CDI)的肠道损伤和炎症,这是一种日益增长的发病率原因, 在美国,死亡率和经济成本是由两种大型梭状芽胞杆菌毒素介导的:TcdA和TcdB。虽然 针对每种毒素的抗体已被证明与保护有关,目前尚不清楚哪种类型的毒素 抗体及其表位对患者对CDI的有效免疫起作用。这样做的目的是 项目是确定CDI中保护性体液免疫反应的特征和主要 中和TcdA和TcdB表位。假设是宿主抗体针对主要的中和作用 TcdA和TcdB中的表位提供了对CDI的保护。为了检验这一假设,我们将首先验证我们的 中和与严重CDI相关保护的抗TcdA/TcdB反应的初步发现 也与预防复发相关(目标1);随后我们将描述艰难梭菌毒素的特异性 B细胞在克隆水平的反应,并与CDI疾病进展和复发相关(目标2); 最后,我们将从单个B细胞中克隆中和抗体,以获得具有代表性的人类 抗这两种毒素的保护性单抗及其结合表位和反应性研究 对艰难梭菌主要流行菌株和暴发菌株产生的各种毒素(目标3)。完成 这些特定的目的可以导致抗体生物标记物的发现,这些抗体生物标记物可以预测大多数 CDI治疗中的重大临床问题,包括CDI的发生、严重程度和复发。 保护性抗体的鉴定和表征也可能促进新型被动抗体的开发 免疫疗法和疫苗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hanping Feng其他文献

Hanping Feng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hanping Feng', 18)}}的其他基金

Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
通过分泌多特异性单域抗体的工程益生菌布拉酵母菌预防诺如病毒和艰难梭菌胃肠炎
  • 批准号:
    10540345
  • 财政年份:
    2020
  • 资助金额:
    $ 38.63万
  • 项目类别:
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
通过分泌多特异性单域抗体的工程益生菌布拉酵母菌预防诺如病毒和艰难梭菌胃肠炎
  • 批准号:
    10320907
  • 财政年份:
    2020
  • 资助金额:
    $ 38.63万
  • 项目类别:
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
艰难梭菌患者中和抗毒素和表位的特征
  • 批准号:
    10319522
  • 财政年份:
    2020
  • 资助金额:
    $ 38.63万
  • 项目类别:
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease
益生菌酵母分泌单域抗体来预防艰难梭菌和空肠弯曲菌疾病
  • 批准号:
    10364713
  • 财政年份:
    2019
  • 资助金额:
    $ 38.63万
  • 项目类别:
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease
益生菌酵母分泌单域抗体来预防艰难梭菌和空肠弯曲菌疾病
  • 批准号:
    10584482
  • 财政年份:
    2019
  • 资助金额:
    $ 38.63万
  • 项目类别:
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection
一种抗艰难梭菌感染的新型人源化四特异性抗体
  • 批准号:
    10432036
  • 财政年份:
    2017
  • 资助金额:
    $ 38.63万
  • 项目类别:
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection
一种抗艰难梭菌感染的新型人源化四特异性抗体
  • 批准号:
    9362547
  • 财政年份:
    2017
  • 资助金额:
    $ 38.63万
  • 项目类别:
Toxemia and systemic disease in Clostridium difficile infection
艰难梭菌感染的毒血症和全身性疾病
  • 批准号:
    8664002
  • 财政年份:
    2013
  • 资助金额:
    $ 38.63万
  • 项目类别:
Epithelium, dendritic cells, and Clostridium difficile associated colitis
上皮、树突状细胞和艰难梭菌相关结肠炎
  • 批准号:
    7887611
  • 财政年份:
    2010
  • 资助金额:
    $ 38.63万
  • 项目类别:
Development of Vaccines against Clostridium difficile Infection
艰难梭菌感染疫苗的研制
  • 批准号:
    7903007
  • 财政年份:
    2010
  • 资助金额:
    $ 38.63万
  • 项目类别:

相似海外基金

Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study
描述 SARS-CoV-2 抗体反应及其与患者因素的关联:参与 GENCOV 研究的参与者的血清学分析
  • 批准号:
    495256
  • 财政年份:
    2023
  • 资助金额:
    $ 38.63万
  • 项目类别:
Understanding the human antibody response to a malaria transmission-blocking vaccine
了解人类抗体对疟疾传播阻断疫苗的反应
  • 批准号:
    MR/X009491/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.63万
  • 项目类别:
    Research Grant
Probing the role of peptidoglycan modification in the antibody response to Staphylococcus aureus
探讨肽聚糖修饰在金黄色葡萄球菌抗体反应中的作用
  • 批准号:
    10549646
  • 财政年份:
    2023
  • 资助金额:
    $ 38.63万
  • 项目类别:
Identification of the antigenic targets of the clonal antibody response to Clostridioides difficile infection
鉴定针对艰难梭菌感染的克隆抗体反应的抗原靶点
  • 批准号:
    10742376
  • 财政年份:
    2023
  • 资助金额:
    $ 38.63万
  • 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
  • 批准号:
    10688292
  • 财政年份:
    2022
  • 资助金额:
    $ 38.63万
  • 项目类别:
Molecular dissection of IgA antibody response by developing monoclonal IgA antibodies from nasal mucosa of mice
通过从小鼠鼻粘膜中开发单克隆 IgA 抗体对 IgA 抗体反应进行分子剖析
  • 批准号:
    22H02875
  • 财政年份:
    2022
  • 资助金额:
    $ 38.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
  • 批准号:
    10634694
  • 财政年份:
    2022
  • 资助金额:
    $ 38.63万
  • 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
  • 批准号:
    10514498
  • 财政年份:
    2022
  • 资助金额:
    $ 38.63万
  • 项目类别:
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
  • 批准号:
    10527979
  • 财政年份:
    2022
  • 资助金额:
    $ 38.63万
  • 项目类别:
Factors related to antibody response of COVID-19 vaccines: with focusing on metabolomics
与 COVID-19 疫苗抗体反应相关的因素:重点关注代谢组学
  • 批准号:
    22H03334
  • 财政年份:
    2022
  • 资助金额:
    $ 38.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了